Biopharma product strategy consultancy Prescient has appointed Shirin Ahmed as Associate Vice President of Real-World Evidence and Medical Affairs Excellence; Erica Carlisle as Vice President and Head of Advisory for the US; and Christian Wasmer as Director and Head of Advisory in Munich.

Prescient works with biopharmaceutical clients to support the development and execution of asset strategy and brand plans. The three new recruits join the firm's Advisory business, which helps biopharma clients develop and commercialize assets and brands.

Ahmed is an epidemiologist by training and has spent twenty years working at pharma companies; most recently at Merck Medical Affairs, leading strategy and execution for its oncology franchise. Carlisle has more than fifteen years' experience in healthcare consulting and biotechnology, including eight years at the Boston Consulting Group, where she served as the North America topic leader for biopharma launches, and most recently serving as VP at Zymergen. Wasmer joins from Trinity Life Sciences, where he served as Engagement Manager, before which, he was a Consultant at Syneos Health, and at Boston Consulting.

Commenting on the appointments, Debasish Talukdar, President and Head of Prescient Advisory, said: 'As we continue to expand our presence and bring the best of product strategy advisory to biopharma clients, we are delighted to welcome Shirin, Erica and Christian as leaders in our rapidly growing team. Their combination of industry expertise, strategic advisory skills and scientific depth make them invaluable assets for the Advisory team as we bring expertise, experience and evidence together to partner with our clients and deliver impact.'

Web site: www.prescienthg.com .

• Printer-friendly version of this article.
• Email this article to a friend.